A forum for researchers, students and applicants in the field of cyclodextrin technology
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Coronavirus SARS-CoV caused an outbreak of severe acute respiratory syndrome (SARS) emerged in Guangdong Province, People’s Republic of China in
University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised
A paper has recently come out open-access in Biomacromolecules reporting on pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents (DOI: 10.1021/acs.biomac.9b01083).
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
Az új koronavírus (SARS-CoV-2) okozta megbetegedés (COVID-19) mára több, mint 65 országot és területet érint, majd 90000 regisztrált megbetegedéssel és
The novel coronavirus SARS-CoV-2 is affecting 65 countries and territories around the world with almost 90,000 reported cases and almost
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
